GSK's Avodart To Get Panel Review For Prostate Cancer Prevention, With Merck's Proscar Along For The Ride
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Oncology Drugs Advisory Committee will review Merck's Proscar (finasteride) as well as GlaxoSmithKline's Avodart (dutasteride), even though Merck has not filed an sNDA.